CG From the

  1. Addressing The GMP Skills Shortage With Virtual Reality 2/14/2024

    In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage  — using virtual reality (VR).

  2. 1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin. 2/12/2024

    By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.

  3. Inside Cell & Gene Live “2024 Regulatory Outlook With FDA’s Dr. Peter Marks And Dr. Nicole Verdun” 1/30/2024

    In case you missed it, our recent Cell & Gene Live, 2024 Regulatory Outlook with FDA’s Dr. Peter Marks and Dr. Nicole Verdun, is available on demand. Here's a summary of the event.

  4. Kriya Therapeutics' Announcements At JPM 1/22/2024

    I caught up with Kriya Therapeutics' Dr. Shankar Ramaswamy to discuss the company's announcements at JPM 2024.

  5. Paving The Way For India’s First Domestic CAR-T Approval 1/22/2024

    India recently saw the approval of its first domestic CAR-T cell therapy, NexCAR19. This not only marks a significant achievement for the country, but for the CGT industry as a whole. To learn more about this journey to approval, I met with ImmunoACT, the pioneer behind NexCAR19.

  6. Treating Heart Disease With Gene Therapy 1/19/2024

    Tenaya Therapeutics' TN-201 is a clinical-stage gene therapy aimed at treating the leading cause of death in the world — heart disease. Tenaya CEO, Faraz Ali, explains the company's journey in developing TN-201, as well as some lessons he's learned throughout his career, and what he's most excited to see in the field heading into 2024.

  7. ARM’s State Of The Industry Briefing At JPM 2024 1/9/2024

    Here's a recap of ARM’s CEO Tim Hunt's 2024 State of the Industry Briefing presentation at JPM 2024.

  8. Cell & Gene: The Podcast Episodes From ARM’s 2023 MOTM 12/21/2023

    All three episodes of Cell & Gene: The Podcast recorded at ARM's 2023 Meeting on the Mesa have now aired. Here's a look at my guests and the important CGT topics we discussed.

  9. iCell, Coeptis On FDA’s Investigation Of CAR T Immunotherapies 12/18/2023

    Last month, the FDA stated it was investigating serious risks of T-cell malignancies in patients following treatment with a chimeric antigen receptor (CAR) T-cell therapies. I met up with Yupo Ma M.D., Ph.D. Chief Scientific Officer at iCell Gene Therapeutics, and Dave Mehalick, CEO and Colleen Delaney, M.D., Chief Scientific and Medical Officer at Coeptis Therapeutics to get their reaction to the FDA’s investigation.

  10. Moving Beyond AAV: The Next Generation Of Vectors In CGT 12/11/2023

    We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.